Introduction: Nasopharyngeal carcinoma (NPC) accounts for 0.01% of all carcinomas, and 70% of patients have locally advanced disease with a poor prognosis. The mainstay therapy is chemoradiotherapy (CRT), and concurrent administration of platinum-based agents and irradiation provides high local control rates. However, induction (neoadjuvant) chemotherapy (ICT) prior to CRT is recommended for large tumors with a high tumor burden at the category 1 level. For ICT, platinum-based doublet or triplet combination regimens are recommended. Selected patients with a high tumor burden at the time of diagnosis who did not receive ICT before CRT were given adjuvant (consolidation) therapy after CRT. This multicenter study aimed to share our experience in treatment of NPC and evaluate the factors associated with survival. Methods: The study included patients diagnosed with NPC who were followed and treated between 2008 and 2022. Hundred and forty-two patients from 6 centers were evaluated. The factors associated with disease-free survival (DFS) and overall survival (OS) were evaluated. Results: The median age of our patients was 51 years (IQR: 16–81 years), and the male:female ratio was 2.5:1. A majority of patients (71%) had stage 3–4 disease. They had locally advanced disease, and 48 patients (34%) received ICT. Twenty patients (14%) received adjuvant therapy. The median follow-up was 41 months (range, 2.7–175.1 months). The median DFS in NPC was 92.6 months (range, 71.9–113.3 months), with a 40th month DFS of 70.9%. The median OS was 113 months (range, 91–135 months), with a 40th month OS of 84.7%. Median DFS was 95.3 months (range, 64.2–126.4 months) in patients who received ICT before CRT, which was longer than in the CRT-only group (p = 0.6). DFS at the 40th month was 75.1% in patients treated with ICT compared to 65.1% in the CRT-only group. Median OS was 117 months (range, 92–142 months) in patients receiving ICT, which was longer than in the CRT-only group (p = 0.4). OS at the 40th month was 86.7% in patients receiving ICT but 83.6% in the CRT-only group. Conclusions: Both the objective response rate and survival were longer in patients who radiologically responded to CRT following ICT. Nonresponse to ICT is a negative predictive indicator. The role of ICT in locally advanced NPC is increasing.

1.
‘Global Cancer Observatory
.
International agency for research on cancer
.
World Health Organization
. Available from: https://gco.iarc.fr/ (accessed on January 23, 2023).
2.
Jiromaru
R
,
Nakagawa
T
,
Yasumatsu
R
.
Advanced nasopharyngeal carcinoma: current and emerging treatment options
.
Cancer Manag Res
.
2022
;
14
:
2681
9
.
3.
Chen
YP
,
Chan
ATC
,
Le
QT
,
Blanchard
P
,
Sun
Y
,
Ma
J
.
Nasopharyngeal carcinoma
.
Lancet
.
2019
;
394
(
10192
):
64
80
.
4.
Barnes
L
,
Eveson
JW
,
Reichart
P
,
Sidransky
D
.
Pathology and genetics of head and neck tumours
.
World health organization classification of tumors
.
Lyon
:
IARC Press
;
2005
.
5.
National Comprehensive Cancer Network
.
NCCN clinical practice guidelines in oncolog y. Head and neck cancer. Version 1.2021
. Available from: https://www.nccn.org/professiona ls/physician_gls/ (Accessed on January 20, 2021).
6.
Tang
LL
,
Guo
R
,
Zhang
N
,
Deng
B
,
Chen
L
,
Cheng
ZB
, et al
.
Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial
.
JAMA
.
2022
;
328
(
8
):
728
36
.
7.
Liu
L-T
,
Liu
H
,
Huang
Y
,
Yang
JH
,
Xie
SY
,
Li
YY
, et al
.
Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
.
Lancet Oncol
.
2023
;
24
(
7
):
798
810
.
8.
Zhang
Y
,
Chen
L
,
Hu
GQ
,
Zhang
N
,
Zhu
XD
,
Yang
KY
, et al
.
Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma
.
N Engl J Med
.
2019
;
381
(
12
):
1124
35
.
9.
Sun
Y
,
Li
WF
,
Chen
NY
,
Zhang
N
,
Hu
GQ
,
Xie
FY
, et al
.
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
.
Lancet Oncol
.
2016
;
17
(
11
):
1509
20
.
10.
Fountzilas
G
,
Ciuleanu
E
,
Bobos
M
,
Kalogera-Fountzila
A
,
Eleftheraki
AG
,
Karayannopoulou
G
, et al
.
Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation
.
Ann Oncol
.
2012
;
23
(
2
):
427
35
.
11.
Hui
EP
,
Ma
BB
,
Leung
SF
,
King
AD
,
Mo
F
,
Kam
MK
, et al
.
Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma
.
J Clin Oncol
.
2009
;
27
(
2
):
242
9
.
12.
Frikha
M
,
Auperin
A
,
Tao
Y
,
Elloumi
F
,
Toumi
N
,
Blanchard
P
, et al
.
A randomized trial of induction docetaxel-cisplatin- 5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)
.
Ann Oncol
.
2018
;
29
(
3
):
731
6
.
13.
Petit
C
,
Lee
A
,
Ma
J
,
Lacas
B
,
Ng
WT
,
Chan
ATC
, et al
.
Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis
.
Lancet Oncol
.
2023
;
24
(
6
):
611
23
.
14.
Eisenhauer
EA
,
Therasse
P
,
Bogaerts
J
,
Schwartz
LH
,
Sargent
D
,
Ford
R
, et al
.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
.
Eur J Cancer
.
2009
;
45
(
2
):
228
47
.
15.
Lu
S
,
Chang
H
,
Sun
X
,
Zhen
Z
,
Sun
F
,
Zhu
J
, et al
.
Long-term outcomes of nasopharyngeal carcinoma in 148 children and adolescents
.
Med
.
2016
;
95
(
17
):
e3445
.
16.
Chang
ET
,
Adami
HO
.
The enigmatic epidemiology of nasopharyngeal carcinoma
.
Cancer Epidemiol Biomarkers Prev
.
2006
;
15
(
10
):
1765
77
.
17.
Wei
WI
,
Sham
JS
.
Nasopharyngeal carcinoma
.
Lancet
.
2005
;
365
(
9476
):
2041
54
.
18.
Su
ZY
,
Siak
PY
,
Leong
CO
,
Cheah
SC
.
The role of Epstein–Barr virus in nasopharyngeal carcinoma
.
Front Microbiol
.
2023
;
14
:
1116143
.
19.
Rossi
A
,
Molinari
R
,
Boracchi
P
,
Del Vecchio
M
,
Marubini
E
,
Nava
M
, et al
.
Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study
.
J Clin Oncol
.
1988
;
6
(
9
):
1401
10
.
20.
Chi
KH
,
Chang
YC
,
Guo
WY
,
Leung
MJ
,
Shiau
CY
,
Chen
SY
, et al
.
A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients
.
Int J Radiat Oncol Biol Phys
.
2002
;
52
(
5
):
1238
44
.
21.
Chitapanarux
I
,
Lorvidhaya
V
,
Kamnerdsupaphon
P
,
Sumitsawan
Y
,
Tharavichitkul
E
,
Sukthomya
V
, et al
.
Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial
.
Eur J Cancer
.
2007
;
43
(
9
):
1399
406
.
You do not currently have access to this content.